This study tests if a web-based app can help patients with early-stage hormone-positive breast cancer stick to their endocrine therapy (ET). ET is a treatment that lowers hormones to prevent cancer from returning. Sometimes, patients stop taking ET because of side effects or not understanding how important it is. This app aims to help by sending reminders and offering videos to teach about side effects and how to handle them.

Key Points:

• The study lasts 3 months with 30 participants.
• Participants will use an internet app alongside their usual care.
• The app provides weekly reminders and educational content about ET.

To join, you must be 18 or older, have early-stage hormone receptor-positive, HER2-negative breast cancer, and have started ET (like aromatase inhibitors or Tamoxifen) within the last 6 months. You also need internet access and speak English. The study is not for those with HER2-positive cancer. This trial could improve understanding and support for ET, making it easier for patients to keep up with their treatment.